Medical Advocates
HIV Infection/Disease
 
Lipodystrophy Drugs

General Reports
Androgen Therapy
Bezafibrate
Growth Hormone
Metformin
 Oxymetholone
Pioglitazone
Rosiglitazone
 Saroglitazar
 Tesamorelin
 Thiazolidinedione
Lipodystrophy Treatment   Main New/Newsworthy Home Page  
Last Update: September 06, 2016
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 

       Journal Papers, Abstracts, and Commentaries

 
Hypolipidemic therapy under special conditions: acquired immune deficiency syndrome.
Yu PC, Calderaro D, Lima EM, Caramelli B. 
Arq Bras Cardiol. 2005 Oct;85 Suppl 4:58-61. Epub 2006 Jan 2.
 Abstract

Pharmacologic Therapy for HIV-Associated Lipodystrophy.
Benavides S, Nahata MC.
Ann Pharmacother. 2004 Jan 30
 Abstract
Androgen Therapy
 
General Reports

       Journal Papers, Abstracts, and Commentaries
 
  Use of androgens in patients who have HIV/AIDS: what we know about the effect of
androgens on wasting and lipodystrophy.
Abrams D.
AIDS Read. 2001 Mar;11(3):149-56.
Abstract
 		  
Bezafibrate
 

       Journal Papers, Abstracts, and Commentaries

  Bezafibrate-induced improvement in glucose uptake and endothelial function in
protease inhibitor-associated insulin resistance.
Nystrom T, Bratt G, Sjoholm A.
J Intern Med 2002 Dec;252(6):570-4
 Abstract		  
Growth Hormone
 

       Journal Papers, Abstracts, and Commentaries

  Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.
Leung V, Chiu YL, Kotler DP, et al
 HIV Clin Trials. 2016 Mar;17(2):55-62
 Abstract

FULL-TEXT ARTICLE
 A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial.
 Lake JE, Tseng CH, Currier JS.
PLoS One. 2013;8(3):e58135.
 Paper

Growth hormone-releasing factor agonists for the treatment of HIV-associated
lipodystrophy.
Hu M, Tomlinson B.
Curr Opin Investig Drugs. 2010 Oct;11(10):1143-1150.
 Abstract

  
Metformin
 

       Journal Papers, Abstracts, and Commentaries

 
Metformin Increases HDL3-Cholesterol and Decreases Subcutaneous Truncal Fat in Nondiabetic
Patients with HIV-Associated Lipodystrophy.
Diehl LA, Fabris BA, Barbosa DS, et al 
AIDS Patient Care STDS. 2008 Sep 18.
 Abstract
 
FULL TEXT ARTICLE
Effect of rosiglitazone and metformin on insulin resistance in patients infected with human
immunodeficiency virus receiving highly active antiretroviral therapy containing protease
inhibitor: randomized prospective controlled clinical trial.
 Silic A, Janez A, Tomazic J, et al
 Croat Med J. 2007 Dec;48(6):791-9.
 Paper
 
Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte
chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy.
Coll B, van Wijk JP, Parra S, rt al
 Eur J Pharmacol. 2006 Jun 16;
 Abstract
 
Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving
protease inhibitor containing HAART.
Tomazic J, Karner P, Vidmar L, Maticic M,
Pharmacol Ther. 2005 Oct 15;22(8):685-700.
Abstract
 
Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.
 van Wijk JP, de Koning EJ, Cabezas MC, et al
Ann Intern Med. 2005 Sep 6;143(5):337-46.
Abstract

FULL-TEXT PDF ARTICLE
Increased PAI-1 and tPA Antigen Levels Are Reduced with Metformin Therapy in
HIV-Infected Patients with Fat Redistribution and Insulin Resistance
Hadigan, JB Meigs JB,  Rabe J, et al.
J Clin Endocrinol Metab. 2001 86: 939-943.
 PSD Paper

Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled
trial.
Hadigan C, Corcoran C, Basgoz N, et al
JAMA 2000 Jul 26;284(4):472-7
 Abstract

  
Pioglitazone
 
      Journal Papers, Abstracts, and Commentaries
 
  Leptin replacement improves postprandial glycemia and insulin sensitivity in human
immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study.
Magkos F, Brennan A, Sweeney L,  et al
Metabolism. 2010 Nov 15
 Abstract
Rosiglitazone
 
     Internet Documents
 
  LETTER
 Rosiglitazone . Adverse Events Warning Letter
GSK
December 2005
PDF Letter

     Journal Papers, Abstracts, and Commentaries

 
Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.
Leung V, Chiu YL, Kotler DP, et al
 HIV Clin Trials. 2016 Mar;17(2):55-62
 Abstract

FULL-TEXT  ARTICLE
Recombinant Human Growth Hormone and Rosiglitazone for Abdominal Fat Accumulation in HIV-Infected Patients with Insulin Resistance: A Randomized, Double-Blind, Placebo-Controlled, Factorial Trial.
 Glesby MJ, Albu J, Chiu YL, , et al
PLoS One. 2013 Apr 12;8(4):e61160
 Paper

The Effect of Rosiglitazone on Insulin Sensitivity, Beta Cell Function, Bone Mineral Density, and
Body Composition in HIV-positive Patients on Highly-active Antiretroviral Therapy (HAART).
Schindler K, Rieger A, Tura A, et al
 Horm Metab Res. 2009 Mar 25.
Abstract
 
FULL TEXT ARTICLE
Effect of rosiglitazone and metformin on insulin resistance in patients infected with human
immunodeficiency virus receiving highly active antiretroviral therapy containing protease
inhibitor: randomized prospective controlled clinical trial.
 Silic A, Janez A, Tomazic J, et al
 Croat Med J. 2007 Dec;48(6):791-9.
 Paper
 
Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte
chemoattractant protein-1 in human immunodeficiency virus-infected patients with
lipodystrophy.
Coll B, van Wijk JP, Parra S, rt al 
Eur J Pharmacol. 2006 Jun 16;
Abstract
 
Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving
protease inhibitor containing HAART.
Tomazic J, Karner P, Vidmar L, Maticic M,
Pharmacol Ther. 2005 Oct 15;22(8):685-700.
Abstract
 
Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.
 van Wijk JP, de Koning EJ, Cabezas MC, et al
Ann Intern Med. 2005 Sep 6;143(5):337-46.
Abstract
 
Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in
HIV-positive patients.
Oette M, Kurowski M, Feldt T, et al
J Antimicrob Chemother. 2005 Jun 27;
 Abstract
 
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular
risk in HIV-infected patients with lipoatrophy.
Kovacic JC, Martin A, Carey D, et aL
Antivir Ther. 2005;10(1):135-43.
Abstract
 
Resistin Levels in HIV-infected Patients with Lipoatrophy Decrease in Response
to Rosiglitazone.
Kamin D, Hadigan C, Lehrke M, et al
J Clin Endocrinol Metab. 2005 Mar 1;
 Abstract

FULL-TEXT PDF ARTICLE
Metabolic Effects of Rosiglitazone in HIV Lipodystrophy: A Randomized,
Controlled Trial.
Hadigan C, Yawetz S, Thomas A,et al.
Ann Intern Med. 2004 May 18;140(10):786-794
 PDF Paper

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind,
placebo-controlled trial.
Carr A, Workman C, Carey D,
Lancet. 2004 Feb 7;363(9407):429-38.
 Abstract
 
Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly
active antiretroviral therapy-associated lipodystrophy.
Sutinen J, Kannisto K, Korsheninnikova E, et al
Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E941-9.
 Abstract
 
FULL-TEXT ARTICLE
Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy
duringrosiglitazone therapy.
Yki-Jarvinen H, Sutinen J, Silveira A, et al
Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):688-94
Paper
 
Improved insulin sensitivity and body fat distribution in HIV-infected patients treated
with rosiglitazone: a pilot study.
Gelato MC, Mynarcik DC, Quick JL, et al
J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):163-70.
 Abstract
Saroglitazar
 

      Journal Papers, Abstracts, and Commentaries

  FULL TEXT ARTICLE
A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.
Deshpande A, Toshniwal H, Joshi S, Jani RH.
PLoS One. 2016 Jan 20;11(1):e0146222.
Paper

FULL TEXT ARTICLE
Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.
Jani RH, Kansagra K, Jain MR, Patel H.
 Clin Drug Investig. 2013 Nov;33(11):809-16.
Paper

The first approved agent in the Glitazar's Class: Saroglitazar.
Agrawal R.
 Curr Drug Targets. 2014 Feb;15(2):151-5.
 Abstract
Tesamorelin (EGRIFTA)
 
     Internet Documents
 
  Facts about EGRIFTA (tesamorelin for injection)
Theratechnologies Inc
Internet Document


NEWS RELEASE
 FDA Approves EGRIFTA (tesamorelin for injection): First and Only Treatment for the
Reduction of Excess Abdominal Fat in HIV-infected Patients with Lipodystrophy
 November 11, 2010
 Internet Document

      Journal Papers, Abstracts, and Commentaries
 
 
FULL TEXT ARTICLE
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.
Mangili A, Falutz J, Mamputu JC,  et al 
PLoS One. 2015 Oct 12;10(10):e0140358.
 Paper

FULL-TEXT ARTICLE
 A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial.
 Lake JE, Tseng CH, Currier JS.
PLoS One. 2013;8(3):e58135.
 Paper

Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy
Spooner LM, Olin JL
 Ann Pharmacother. 2012 Jan 31
 Abstract

Tesamorelin: A Review of its Use in the Management of HIV-Associated Lipodystrophy.
Dhillon S.
Drugs. 2011 May 28;71(8):1071-91
 Abstract

Effects of Tesamorelin on Inflammatory Markers in HIV Patients with Excess Abdominal Fat:
Relationship with Visceral Adipose Reduction.
Stanley TL, Falutz J, Mamputu JC,  et al
AIDS. 2011 Apr 21.
 Abstract

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients
with abdominal fat accumulation.
Falutz J, Allas S, Mamputu JC,et al
AIDS. 2008 Aug .
 Abstract

TH9507: an experimental treatment for lipodystrophy.
Monroe A.
BETA. 2007 Summer;19(4):16-9.
 Abstract
 
FULL-TEXT ARTICLE
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Falutz J, Allas S, Blot K, et al
N Engl J Med. 2007 Dec 6;357(23):2359-70.
Paper
 
Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor
analogue.
Ferdinandi ES, Brazeau P, High K, et al
Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):49-58
 Abstract
 
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.
Tomlinson B.
Curr Opin Investig Drugs. 2006 Oct;7(10):936-45.L
 Abstract
 
 
Thiazolidinedione
 
       Journal Papers, Abstracts, and Commentaries
 
  The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients.
Sutinen J.
PPAR Res. 2009;2009:373524.
Abstract

Lipodystrophy Treatment   Main New/Newsworthy Home Page  

Lipodystrophy Drugs